Ken Griffin Elevation Oncology, Inc. Call Options Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
Call Options
1 transactions
Others Institutions Holding ELEV
# of Institutions
68Shares Held
45.4MCall Options Held
700Put Options Held
27.6K-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.99MShares$3.6 Million0.19% of portfolio
-
Tang Capital Management LLC San Diego, CA4.76MShares$2.86 Million0.24% of portfolio
-
Goldman Sachs Group Inc New York, NY3.99MShares$2.39 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.53MShares$2.12 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.07MShares$1.84 Million0.0% of portfolio
About Elevation Oncology, Inc.
- Ticker ELEV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,300,900
- Market Cap $14M
- Description
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...